pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,109 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1183Endpoints901BioPharma Dive347BioSpace317Fierce Biotech301onclive165raps106globenewswire health
therapy area
allOncology7751Rare Disease1885Cardiology1770Immunology1511Hematology1328Vaccines1204Pulmonology
  • Septuagenarian begins family-medicine residency at 72 after 45-year nursing career
    Dawn Zuidgeest-Craft, a former neonatal nurse practitioner, finally entered medical school at age 69 after decades of clinical work and personal life events. She graduated in 2025 and, despite not…
    STAT · 3mo agoPositive↗ source
  • Ending federally funded animal testing could stall xenotransplantation breakthroughs
    Transplant surgeon Joshua Mezrich argues that recent moves to end federally funded animal testing could impede the development of xenotransplantation, a field that aims to use pig organs for human…
    STAT · 3mo agoRegulatoryNegative↗ source
← prev
page 62 of 85
next →
73
fda recalls70
fda medwatch60
fda press38
1200
Psychiatry & CNS870
Ophthalmology502
Pain482
Endocrinology & Metabolism481
Infectious Disease444
  • GSK to acquire cancer-focused biotech Nuvalent for $10.6 billion
    GSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
    STAT · 3mo agoDealPositive↗ source
  • U.S. drug shortages drop 23% but average duration climbs to over five years, analysis shows
    The latest U.S. Pharmacopeia analysis reports that the total number of prescription drug shortages fell by 23% last year, marking the second year of decline and the lowest level since 2017. Despit…
    STAT · 3mo agoNegative↗ source
  • Trump’s health-care affordability czar targets hospitals, raises concerns over suppressed alcohol study
    The piece reports that the Trump administration’s health‑care affordability czar has begun scrutinizing hospitals, signaling a new push to control costs and improve price transparency. The czar’s…
    STAT · 3mo agoRegulatoryNegative↗ source
  • FDA approves first new sunscreen ingredient in over 25 years
    The U.S. Food and Drug Administration has cleared a new sunscreen active called bemotrizinol, the first novel ingredient to receive approval in more than a quarter‑century. The agency said the che…
    STAT · 3mo agoRegulatoryPositive↗ source
  • GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipeline
    GSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
    STAT · 3mo agoDealNeutral↗ source
  • GSK to acquire cancer drug developer Nuvalent for $10.6 billion
    GSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…
    STAT · 3mo agoDealNeutral↗ source
  • Dexcom trial shows continuous glucose monitors improve outcomes across diabetes types
    Dexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to stan…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Trump health-care czar touts $510 billion Medicaid cut, warns hospitals of financial strain
    At a Healthcare Financial Management Association conference in National Harbor, Maryland, the Trump administration’s newly appointed health-care affordability czar addressed hospital finance leader…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Former USAID Ebola adviser says lessons from 2014 are fading as new outbreak spreads in DRC and Uganda
    In October 2014 Susan Reichle served as a counselor to USAID in Washington, D.C., when the CDC launched its largest ever Ebola response. She contrasts that crisis with the current outbreak in the…
    STAT · 3mo agoNeutral↗ source
  • ADA ejects five diabetes experts for distributing editorial criticizing NIH research cuts
    Security personnel removed five diabetes researchers from the American Diabetes Association's annual meeting in New Orleans after they handed out copies of an editorial that condemned recent federa…
    STAT · 3mo agoNegative↗ source
  • Federal alcohol study finds low-level drinking may raise disease risk, faces political pushback
    STAT’s Morning Rounds reported that a federally commissioned study on alcohol’s health effects was published today in an independent journal. The researchers concluded that even modest alcohol cons…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Trump administration threatens fines for over 500 hospitals that fail to disclose pricing
    The Trump administration has warned more than 500 hospitals that they are not providing the public with basic pricing information, the Associated Press reported. Hospitals that fail to create a pl…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH names John Powers III as acting director of NIAID amid leadership uncertainty
    The National Institutes of Health has appointed researcher John Powers III to serve as acting director of the National Institute of Allergy and Infectious Diseases (NIAID). Powers previously served…
    STAT · 3mo agoNeutral↗ source
  • Oura and Whoop add in-app virtual doctor visits, moving wearable data toward clinical use
    Wearable makers Oura and Whoop announced that users will soon be able to connect with doctors through their apps, allowing virtual consultations when a device flags a health concern. The new featu…
    STAT · 3mo agoNeutral↗ source
  • Trump-suppressed alcohol health study released, finds low-level drinking may raise disease risk
    A federal study on alcohol's health effects, commissioned by SAMHSA in 2023 to inform U.S. dietary guidelines, has finally been published in a scientific journal after being withheld by the Trump a…
    STAT · 3mo agoRegulatoryNegative↗ source
  • NIH staff say leadership ignored dissent letter a year after Bethesda Declaration
    A new report released on the one‑year anniversary of the Bethesda Declaration says NIH leadership has largely ignored the concerns raised by staff in their open letter of dissent. The report, titl…
    STAT · 3mo agoNegative↗ source
  • STAT chooses to keep health care as two words despite AP stylebook shift
    The Associated Press updated its style guide in April, merging health care into the single word healthcare. The change sparked discussion among journalists and readers. At STAT, the editorial staf…
    STAT · 3mo agoNeutral↗ source
  • J&J to buy Firefly Bio for $1 billion to boost KRAS inhibitor program
    J&J announced Monday it will acquire biotech startup Firefly Bio for $1 billion, aiming to broaden its KRAS inhibitor portfolio. The move follows recent data from Revolution Medicines showing a KR…
    STAT · 3mo agoDealPositive↗ source
  • Financing gaps keep $2 million gene therapies out of reach for many patients
    William Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…
    STAT · 3mo agoNegative↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 3mo agoNegative↗ source
  • Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition
    Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
    STAT · 3mo agoNeutral↗ source